Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

orward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward- looking statements.

Plavix(R)/Iscover(R) are registered trademarks of Sanofi-Synthelabo Inc. Effient(TM) is a trademark of Eli Lilly and Company.

P-LLY

(i) American Heart Association. Heart Disease and Stroke Statistics -

2006 Update. Dallas, TX. American Heart Association.

(ii) Bertrand CURE study

(iii) American Heart Association. Heart Attack and Angina Statistics.

URL: http://www.americanheart.org/presenter.jhtml?identifier=4591.

Last accessed July 26, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LONDON , August 3, 2015 ... Portland Hospital waved the shortfall of ... fanatic could stand normally for the first time. ...      (Photo: http://photos.prnewswire.com/prnh/20150803/254229 ) The ... Jude,s legs allowing him to carry out his wish ...
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... to treat life-threatening diseases, today announced that it will ... and webcast on Thursday, August 13, 2015 at 4:30 ... will follow the release of fiscal 2016 first quarter ... available approximately two hours after the call at the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the ... line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, ... resistant and maintenance-free solution for a broad range of vacuum filtration applications. , ...
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
Breaking Biology Technology:Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... a privately,held biotechnology company, announced that it has ... Series D preferred stock offering with its investor,syndicate ... Ventures,L.P., Boston Medical Investors and Silicon Valley Bank ... Chairman of the Board. The Company,expects a second ...
... Application in the ... European Union, ... Food and Drug Administration (FDA) has approved the design of,a single, ... with chemotherapy as first-line,treatment in patients with non-small cell lung cancer ...
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
Cached Biology Technology:Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5Pharmaxis' Aridol Gains First Asian Approval 2
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... (Sept. 4, 2008) A variety of organismsfrom ... where the timing and duration of fundamental biological processes ... survive, even under fluctuating environmental conditions. In recent ... molecular basis of these rhythms and how they translate ...
... Breast Cancer Symposium features the latest cutting-edge findings in ... meeting focuses on new and promising therapeutic approaches, as ... breast cancer. To help you take the best ... we encourage you to visit www.sabcs.org to ...
... September 4, 2008) The tumor suppressor gene ... in cases of soft tissue sarcoma (STS), according ... at the Sbarro Institute for Cancer Research and ... Technology at Temple University in Philadelphia, PA, the ...
Cached Biology News:Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2International team reveals first prognosticator of survival in aggressive cancer 2
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
LTBP-2 (7B10)...
... Product Rabbit polyclonal to Kv4.2 ... to KLH, corresponding to amino acids 23-43 ... Cross-reacts with Rat.Expected to cross-react with ... identity with immunogen), Rabbit (100% identity with ...
Mouse Anti-Gemin2...
Biology Products: